Avingtrans appoints Stuart Gall as CEO of medical imaging division

Avingtrans Plc (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced the appointment of Stuart Gall as Divisional Chief Executive Officer of its medical imaging businesses division, including Adaptix Ltd and Magnetica Ltd, with effect from on or before 10 March 2026.

Stuart was previously Chief Executive Officer of Intelligent Ultrasound Group plc, a medical technology company focused on ultrasound simulation and artificial intelligence-based image analysis. He has significant experience in the development and commercialisation of novel medical imaging technologies and in leading companies from spin-out stage to public markets.

Steve McQuillan, CEO of Avingtrans, commented: “We are pleased to welcome Stuart to Avingtrans and look forward to him joining the business formally. His experience and leadership in scaling medical imaging technologies will support the continued development of Adaptix and Magnetica as they move towards commercialisation.”

Share on:

You might also enjoy reading Avingtrans reports record revenue and earnings growth in FY25

Written by: Amilia Stone

Latest Company News

Avingtrans Plc Building Momentum in Nuclear and Medical Imaging as Margins Surge (Video)

February 26, 2026

Avingtrans delivered improved margins and earnings in the first half, supported by stronger aftermarket activity and disciplined debt control. While revenue was flat year-on-year, management expects the usual second-half weighting to return, aided by nuclear contracts and rising data centre cooling demand. With Adaptix now FDA approved and US distributors appointed, medical imaging enters a critical commercial phase alongside growing exposure to AI-driven nuclear build-out.

Avingtrans reports higher interim profit and strong FY26 visibility

February 25, 2026

Avingtrans PLC reported flat first-half revenue of £78.1m for the six months to 30 November 2025, with adjusted EBITDA up 10.4% to £9.6m and adjusted profit before tax rising 27.1% to £5.7m.

Avingtrans appoints Stuart Gall as CEO of Medical and Industrial Imaging division

January 12, 2026

Avingtrans plc has announced that Stuart Gall officially assumed the role of Chief Executive Officer of its medical and industrial imaging division on 1 January 2026.

Avingtrans subsidiary Adaptix gains FDA clearance for Ortho350

November 10, 2025

Avingtrans reported that its subsidiary Adaptix has received FDA 510(k) clearance for the Ortho350, a compact 3D orthopaedic imaging system designed for point of care use.

Avingtrans CEO on record revenue and strong order book momentum for FY25 (LON:AVG)

October 2, 2025

Avingtrans has delivered record revenue of £156.4 million for FY25, with Chief Executive Officer Steve McQuillan highlighting robust order book growth, major contract wins, and increasing demand across energy, defence, infrastructure and medical divisions.

Avingtrans appoints Stuart Gall as CEO of medical imaging division

September 29, 2025

Avingtrans Plc has announced the appointment of Stuart Gall as Divisional Chief Executive Officer of its medical imaging businesses, including Adaptix and Magnetica, effective on or before 10 March 2026.